Auris Medical reporting results of phase I/II clinical trial with AM-101

Sound Pharmaceuticals (SPI) has received FDA notification that it may proceed with its Phase II stud

Quark Closes $27 Million Financing

GenVec announces NIH funding

GenVec, a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines, has attracted NIH funding to develop their gene-based drug research for hearing loss and balance.

Company Spotlight - GenVec

Douglas E. Brough, Senior Director Vector Sciences from GenVec talks to RNID about how they are using the expression of the atonal gene in the inner-ear to regenerate sensory hair cells.

Auris Medical

Auris Medical is dedicated to the development of novel pharmaceutical therapies to prevent or treat severe inner ear disorders.

Tinnitus market report updated

We have produced an updated version of our tinnitus market report. The report is aimed at pharmaceutical and biotech companies interested in developing treatments for tinnitus.

Adherex

Adherex Technologies Inc. announced on 30 October 2007 the launch of a Phase III trial of sodium thiosulfate (STS) in children with hepatoblastoma (liver cancer).

Merz announce results

Merz an independent German pharmaceutical company has just announced promising results for Neramexane.